INFLARX N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.43 USD | -.--% |
|
-0.69% | -12.27% |
| May. 08 | InflaRx N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 21 | Transcript : InflaRx N.V. - Special Call |
| Sales 2024 * | 407K 441K | Sales 2025 * | 1.37M 1.49M | Capitalization | 77.64M 84.2M |
|---|---|---|---|---|---|
| Net income 2024 * | -46M -49.89M | Net income 2025 * | -61M -66.15M | EV / Sales 2024 * | 64.1 x |
| Net cash position 2024 * | 51.55M 55.91M | Net cash position 2025 * | 7.3M 7.91M | EV / Sales 2025 * | 51.3 x |
| P/E ratio 2024 * |
-1.78
x | P/E ratio 2025 * |
-1.54
x | Employees | 62 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on InflaRx N.V.
More recommendations
More press releases
More news
| 1 week | -0.69% | ||
| 1 month | +4.38% | ||
| 3 months | -19.66% | ||
| 6 months | +5.93% | ||
| Current year | -12.27% |
1 week
1.37
1.53
1 month
1.171.72
Current year
1.172.10
1 year
1.144.70
3 years
0.787.25
5 years
0.7837.47
10 years
0.7853.10
| Managers | Title | Age | Since |
|---|---|---|---|
Renfeng Guo
FOU | Founder | 53 | 07-11-30 |
Niels Riedemann
FOU | Founder | 51 | 07-11-30 |
Thomas Taapken
DFI | Director of Finance/CFO | 59 | 20-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nicolas Fulpius
FOU | Founder | 51 | 07-11-30 |
Niels Riedemann
FOU | Founder | 51 | 07-11-30 |
Renfeng Guo
FOU | Founder | 53 | 07-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 1.43 | -.--% | 298,879 |
| 24-05-30 | 1.43 | -2.05% | 276,209 |
| 24-05-29 | 1.46 | -.--% | 262,919 |
| 24-05-28 | 1.46 | +1.39% | 192,536 |
| 24-05-24 | 1.44 | -2.70% | 209,759 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Calendar
2024-06-05
- R&D Day
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.319
EUR
Average target price
8.375
EUR
Spread / Average Target
+535.12%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.27% | 84.2M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- IFRX Stock
